Literature DB >> 6998708

Time course of blood pressure, pulse rate, plasma renin and metoprolol during treatment of hypertensive patients.

K Haglund, P Collste.   

Abstract

Eleven patients were treated for essential hypertension with metoprolol (Selokén) for more than three months. The time course of changes in blood pressure, pulse rate and plasma renin activity was studied during treatment with an oral maintenance dose of 100 mg twice daily. Significant decreases in pulse rate, diastolic blood pressure and plasma renin activity were observed even after the first dose. The plasma concentration of metoprolol reached equilibrium after the second dose. After the third dose there was no further significant change in blood pressure. There was a significant correlation (p < 0.001) between the initial (after three doses) and final (after > 90 days) effect of metoprolol on blood pressure (r = 0.86 and 0.91 for systolic and diastolic blood pressure change, respectively).

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6998708     DOI: 10.1007/bf00558443

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  29 in total

1.  Long term beta-adrenergic blockade reduces tyrosine hydroxylase and dopamine beta-hydroxylase activities in sympathetic ganglia.

Authors:  A E Raine; I W Chubb
Journal:  Nature       Date:  1977-05-19       Impact factor: 49.962

2.  Reduction in sympathetic nervous activity as a mechanism for hypotensive effect of propranolol.

Authors:  P J Lewis; G Haeusler
Journal:  Nature       Date:  1975-07-31       Impact factor: 49.962

3.  Quantitative determination of metoprolol in plasma and urine by gas chromatography.

Authors:  M Ervik
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1975

4.  Beta-adrenergic blockade in diuretic-treated patients with essential hypertension.

Authors:  E L Bravo; R C Tarazi; H P Dustan
Journal:  N Engl J Med       Date:  1975-01-09       Impact factor: 91.245

5.  The effects of atenolol (tenormin) and methyldopa on simple tests of central nervous function.

Authors:  P F Bayliss; S M Duncan
Journal:  Br J Clin Pharmacol       Date:  1975-12       Impact factor: 4.335

6.  Effects of acute and chronic administration of propranolol on blood pressure and plasma renin activity in hypertensive patients.

Authors:  G S Stokes; M A Weber; I R Thornell; L M Stoker
Journal:  Prog Biochem Pharmacol       Date:  1974

7.  Plasma levels and effects of metoprolol after single and multiple oral doses.

Authors:  P Collste; K Haglund; C von Bahr
Journal:  Clin Pharmacol Ther       Date:  1980-04       Impact factor: 6.875

8.  Comparison of the antihypertensive and hormonal effects of a cardioselective beta-blocker, acebutolol, and diuretics in essential hypertension.

Authors:  F Alhenc-Gelas; P F Plouin; M B Ducrocq; P Corvol; J Menard
Journal:  Am J Med       Date:  1978-06       Impact factor: 4.965

9.  Haemodynamic long-term effects of metoprolol at rest and during exercise in essential hypertension.

Authors:  P Lund-Johansen; O J Ohm
Journal:  Br J Clin Pharmacol       Date:  1977-04       Impact factor: 4.335

10.  Beta-adrenergic receptor blocking drugs, hypertension and plasma renin.

Authors:  T O Morgan; R Roberts; S L Carney; W J Louis; A E Doyle
Journal:  Br J Clin Pharmacol       Date:  1975-04       Impact factor: 4.335

View more
  3 in total

1.  Decreased plasma concentrations and clinical effects of alprenolol during combined treatment with pentobarbitone in hypertension.

Authors:  P Seideman; K O Borg; K Haglund; C Von Bahr
Journal:  Br J Clin Pharmacol       Date:  1987-03       Impact factor: 4.335

2.  The effects of acute or chronic ingestion of propranolol or metoprolol on the physiological responses to prolonged, submaximal exercise in hypertensive men.

Authors:  R G Wilcox; T Bennett; I A Macdonald; M Herbert; A M Skene
Journal:  Br J Clin Pharmacol       Date:  1984-03       Impact factor: 4.335

Review 3.  Metoprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in hypertension, ischaemic heart disease and related cardiovascular disorders.

Authors:  P Benfield; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1986-05       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.